171results about How to "Significant antidepressant effect" patented technology

The invention relates to a trace element water-soluble fertilizer and a preparation method thereof, which are applied in the field of agriculture and forestry production. The trace element water-soluble fertilizer is characterized by comprising the following components in percentage by weight: 13 to 20 percent of ammonium carbonate, 8 to 10 percent of monopotassium phosphate, 19 to 35 percent of potassium sulfate, 15 to 33 percent of ferrous sulfate, 1.5 to 2.0 percent of copper sulfate, 1.9 to 2.5 percent of zinc sulfate, 1.6 to 1.9 percent of manganese sulfate, 2.3 to 2.6 percent of boric acid, 0.1 to 0.2 percent of sodium molybdate, 13 to 17 percent of magnesium sulfate, 1.5 to 2.0 percent of pericarpium juglandis, 2.0 to 2.5 percent of rhubarb, 1.5 to 1.8 percent of fineleaf schizonepeta herb and 1.0 to 1.4 percent of peganum harmala. The preparation method comprises the following steps of: 1, evaporating and dehydrating the ammonium carbonate, monopotassium phosphate, potassium sulfate, ferrous sulfate, copper sulfate, zinc sulfate, manganese sulfate, boric acid, sodium molybdate and magnesium sulfate at the temperature of between 110 and 180 DEG C respectively to keep the water content below 1.5 percent, and crushing the components into fine powder respectively; 2, crushing the pericarpium juglandis, rhubarb, fineleaf schizonepeta herb and the peganum harmala into fine powder, boiling the fine powder for 1 to 2 hours by adding water, squeezing the mixture, and taking juice to form Chinese medicinal juice; and 3, mixing the treated raw materials in a ratio, and winnowing and crushing the mixture to obtain the trace element water-soluble fertilizer.

The present invention relates to a new-type high-effective safety medicine-ginkgo leaf total lactone for curing depression. It is a terpene lactone extracted from ginkgo biloba. L or other portions of said plant, such as ginkgo nut, ginkgo root bark and ginkgo twing, in which five terpene lactone compounds of bilobalide A, bilobalide B, bilobalide C, bilobalide J and bilobalide are mainly contained.

The invention provides an application of a combined drug composition of ketamine or S-(+)-ketamine or a pharmaceutically acceptable salt of ketamine or S-(+)-ketamine, and escitalopram or a pharmaceutically acceptable salt of escitalopram, to the preparation of drugs for treating major depressive disorder. The major depressive disorder can be major depressive disorder breaking out for the first time, major depressive disorder breaking out again or refractory depression. The invention furthermore provides an application of ketamine or S-(+)-ketamine or the pharmaceutically acceptable salt of ketamine or S-(+)-ketamine to the preparation of the drugs for treating the major depressive disorder, and a drug preparation containing ketamine or S-(+)-ketamine or the pharmaceutically acceptable salt of ketamine or S-(+)-ketamine, and escitalopram or the pharmaceutically acceptable salt of escitalopram. Ketamine and conventional antidepressants are used together; and a proper amount of ketamine is intravenously injected once at first day of start of treatment, so that the anti-depression effect of oral antidepressants can be effectively improved, the effect display lag period is remarkably shortened, and suicidal actions of patients can be remarkably reduced.

The invention discloses the use of C21 steroid glycoside in pharmacy, wherein the systematic test shows that C21 steroid glycocide has low toxic and side effect, but has unique effect for treating psychogenia diseases with depression state, in particular for depression.

The present invention relates to kind one ginsenoside Rg2 preparing process suitable for industrial production, and gradient salt separation process with simple operation is used in substituting traditional silicon gel chromatography process. The present invention also relates to medicine composition with ginsenoside Rg2 as active component and its application in medicine for preventing and treating dementia, depression, peripheral circulation disturbance and related diseases.

The invention discloses novel 3-cyclopropylmethoxy-4-alkoxybenzamide PDE (phosphodiesterase) 4 inhibitors. The inhibitors are compounds represented in a general formula I or a general formula II, prodrugs thereof, pharmaceutically usable salts thereof or solvates thereof, wherein R<1> is independent methyl (Me-) or difluoromethyl (CF2H-); R<2> is independent H, Me or Et; R<3> is independent H, MeO or Cl; CnH(2n+2) is alkyl, and N is larger than or equal to 2; a substance shown in the specification is a substituted benzene ring or pyridine ring; X is C or N; Y is C or N. The novel 3-cyclopropylmethoxy-4-alkoxybenzamide PDE 4 inhibitors have the advantages of high in-vitro enzyme inhibition activity, capability of selective application to PDE4 and good anti-inflammation effect and anti-depression effect.

The present invention provides a novel compound and antidepressant composition that can be effectively used for improving depressed mood and depressed state, particularly for depressed mood and depressed state in menopausal women. The compound of the present invention is represented by the following formula (1):wherein R1 and R2 are identical or different and represent a hydrogen atom, a hydroxyl group or an acetyloxy group, and n is an integer of 2 to 7,or a pharmaceutically acceptable salt or ester thereof. This compound is used as an active ingredient in the antidepressant composition. Examples of the compound of the invention include (2E)-9,10-dihydroxy-2-decenoic acid, (2Z)-9,10-dihydroxy-2-decenoic acid, (2E)-9-hydroxy-2-decenoic acid, and (2E)-7-acetoxy-2-heptenoic acid.

The invention discloses an application of Akkermansia Muciniphila in the preparation of drugs for preventing depression or health products. In vivo pharmacodynamic studies are performed on the effectsof Akkermansia Muciniphila bacteria in depression and anti-depression; results show that the Akkermansia Muciniphila abundance in the intestinal tracts of depression patients is obviously reduced; and animal experiment results show that the Akkermansia Muciniphila abundance in the intestinal tracts of mice is obviously reduced. The Akkermansia Muciniphila bacteria are transplanted to a depressionmouse model, and experiments show that the transplantation of the Akkermansia Muciniphila bacteria can increase the movement distances of the mice and reduce the dead time of tail suspension tests and forced swimming tests, and the depression states of the mice can be significantly alleviated, so that the Akkermansia Muciniphila bacteria show good anti-depression curative effects and has no side-effects yet.

The invention discloses a pharmaceutical composition for treating and preventing depression and a preparation method of the pharmaceutical composition. The composition consists of radix bupleuri extract, Chinese angelica extract and white atractylodes rhizome extract. According to the pharmacological experiment results, the pharmaceutical composition can be used for obviously reducing dead time in a mouse forced swimming test and a mice hanging test, remarkably increasing chronic temperature and the weight and the sweet water eccentricity of an unpredictable depression model, and has an obvious anti-depression effect which can reach or exceed that of the existing clinical common anti-depression drugs.

Compositions and methods use Bifidobacterium longum NCC3001 (ATCC BAA-999) to treat or prevent a depressive symptom. Prolonged anti-depressive effects can continue after administration of the compositions is ended. Non-limiting examples of a depressive symptom which can be treated or prevented include depressed mood; sadness; anxiety; "empty" feelings; loss of interest or pleasure; irritability; restlessness; changes in appetite or weight; sleep disturbances; lack of or decreased energy; feelings of worthlessness; guilt; helplessness; anger and hostility; difficulty in thinking, concentrating,or making decisions; hopelessness; tiredness; fatigue; memory difficulties; tearfulness; brooding; phobias; excessive worry over physical health; sexual dysfunction; persistent physical symptoms thatdo not respond to treatment; and combinations thereof. These depressive symptoms can be associated with a depressive state or depressive disorder or can be found sub-clinically or not associated withthese depressive states / disorders (e.g., not part of a syndrome or psychiatric disorder).

The invention relates to a Chinese medicinal compound for treating recession, the preparing process and use, wherein the medicinal composition comprises (by weight portions): bupleurum root 2-4 parts, white peony root 3-5 parts, Chinese angelica root 3-5 parts, mimosa-tree bark 3-5 parts, polygala root 2-4 parts, poria cocos wolf 2-4 parts, acorus gramineus soland 2-4 parts.

The invention discloses an application of norketamine in preparation of an antidepressant drug. The antidepressant drug comprises an effective dose of norketamine and pharmaceutically acceptable auxiliary materials. According to the application of the norketamine in preparation of the antidepressant drug, the anti-depression effect of the norketamine is superior to that of ketamine, the depressionsymptoms can be relieved to a certain extent by reducing expression and activity of TNF-alpha, and meanwhile, the side effect of the norketamine is lower than that of the ketamine. The research results show that the norketamine can provide a new antidepressant drug for clinic application.

The invention provides new application of sea-buckthorn seed oil extracted from sea-buckthorn seeds, i.e., application of the sea-buckthorn seed oil to preparation of a medicament or a health-care food for preventing and / or treating depression, and application of the sea-buckthorn seed oil serving as a raw material to preparation of the medicament or the health-care food for preventing and / or treating the depression. Test results prove that the immobility time in forced swimming tests of mice and tail suspension tests of the mice can be obviously reduced by the sea-buckthorn seed oil and the sea-buckthorn seed oil has an obvious depression suppression effect. The sea-buckthorn seed oil is a natural anti-depression effective substance which has the advantages of easiness and convenience in preparation, obvious effect, safety, reliability and easiness for industrial production. The sea-buckthorn seed oil can be prepared into formulations such as soft capsules, dropping pills and emulsion for anti-depression medicaments or health care foods.

The invention discloses a Chinese herba preparation for treating depression. The Chinese herba preparation is prepared by the following raw materials in parts by weight: 10-14 parts of rhizoma anemarrhenae, 13-17 parts of radix rehmanniae, 8-12 parts of radix paeoniae alba, 23-27 parts of keel, 28-32 parts of oyster, 8-12 parts of golden cypress, 10-14 parts of gardenia, 10-14 parts of wolfberry fruit and 10-14 parts of macrocarpium fruit. The Chinese herba preparation has favorable effect in treating depression, little reverse reaction, light degree, small side effect, good tolerance and highobedience for patients to take the medicine.

The invention belongs to the field of medicine and health and particularly relates to the use of a natural compound, namely a ginsenoside monomer Rg1, in the preparation of an antidepressant. A test dose of ginsenoside Rg1 can reduce dead time of a mouse in a tail suspension experiment and obviously reduce the dead time of a mouse in a forced swimming experiment and the times of escape failures of a mouse in a learned helplessness experiment, which shows that the ginsenoside Rg1 has a remarkable antidepressant effect and can be used for preventing and treating depression.

The invention discloses a preparation method of hypericum perforatum extractive which is rich in hyperforin, which comprises the following steps of: taking the hypericum perforatum crude extractive which is sold in the market as the raw material; ultrasonically extracting in the ice water bath; preliminarily removing the impurity by means of two-phase extraction and the like to obtain 11-18% hyperforin-containing extractive; and separating and purifying by means of the silica column chromatography technology to obtain 37-57% hyperforin-containing extractive. The pharmacological test proves that the extractive has the functions of the depression resistant and the learning and memorizing promotion. The preparation method is simple and easy, is suitable for the small-scale preparation required by the pharmacological test and the like, and can save the extracting time and space.

The invention discloses a composite microbial preparation and application thereof in relieving depression and constipation, and belongs to the technical field of microorganisms. The prepared compositeprobiotics can reduce the concentration of adrenal release promoting hormone and corticosterone in serum of mice and relieve depression and anxiety behaviors caused by chronic pressure; the compositeprobiotics can up-regulate the expression of intestinal tract Htr4 genes, so that the intestinal tract peristalsis capacity of mice is improved; the content of short-chain fatty acid in intestinal tracts can be increased, and constipation can be remarkably improved; the gene expression of intestinal tract tight junction proteins ZO-1, Occludin and Claudin-1 can be improved, the intestinal tract permeability can be reduced, and peripheral and central nervous system inflammations can be reduced; the level of 5-HTP in intestinal tracts, serum and brains can be improved, and the potential of improving sleep is achieved. The composite probiotics prepared by the invention have wide application values in the aspects of resisting depression and anxiety, relieving constipation, resisting inflammation, improving sleep and the like.

The invention provides application of illicium macranthum alcohol in preparation of a medicine for treating depression and belongs to the technical field of medicines. The illicium macranthum alcohol has the characteristics of wide source and low cost; the illicium macranthum alcohol serves as a natural medicine, serves as a traditional medicine to be durably used, namely the illicium macranthum alcohol serves as a medicine and has high using safety; and moreover, the illicium macranthum alcohol has a good depression treatment effect, so that the illicium macranthum alcohol can serve as a depression treatment medicine or a related lead compound and is used for pharmaceutical production, and the source of the natural depression treatment medicines is widened.

The invention belongs to the technical field of medicines and provides application of dendrobium officinale polysaccharides to preparation of antidepressant medicines and antidepressant healthcare products. Dendrobium officinale is used as a natural medicine and food for a long time and high in safety when serving as a medicine and a healthcare product. The dendrobium officinale polysaccharides have an excellent antidepressant effect, thereby being used for pharmaceutical production or healthcare product production as antidepressant medicines and antidepressant healthcare products. Further, sources of the antidepressant natural medicines and antidepressant healthcare products are broadened.

The invention relates to the technology of pharmacy, and particularly relates to application of oridonin in preparation of anti-depression medicines. The anti-depression medicinal ingredient of the anti-depression medicine provided by the invention is oridonin, and has an efficacy dosage 0.01-30mg oridonin per kilogram of the body weight; and an anti-depression effect can be generated in 60 minutes after the medicine is administrated. The medicine has the advantages of remarkable anti-depression effect, quick response, small dosage, small side effect and the like. In a mammal mouse tail suspension test, the oridonin has a more remarkable anti-depression effect than that of conventional anti-depression medicine imipramine, and is expected to become a novel quick and efficient anti-depression medicine without toxic or side effect.

The invention discloses a traditional Chinese medicine for treating depression, which is prepared by the following traditional Chinese medicine raw materials in parts by weight: 10-14 parts of longanfruit, 10-14 parts of fried jujube kernels, 8-12 parts of polygalae, 8-12 parts of platycladi seed, 3-7 parts of radix glycyrrhizae preparata, 8-12 parts of ginseng, 10-14 parts of astragalus root, 13-17 parts of tuckahoe, 10-14 parts of atractylodis and 8-12 parts of angelica. The traditional Chinese medicine features good antidepressive therapeutic effect, little adverse reaction, slight degree,few side effects, good tolerability and high compliance of patients during drug administration.

The invention discloses a compound preparation with an auxiliary effect of preventing and treating psychological depression of children and adolescents. The compound preparation comprises probiotic mineral powder, which comprises mineral and terpene components, a medicinal and edible component, a probiotic component and a vitamin component. Clinical contrast tests show that the compound preparation can well reduce the depression HAMD score of children and adolescents. Pharmacological tests of depression model mice show that the compound preparation provided by the invention obviously shortensthe immobility time of tail suspension in mice and obviously shortens the immobility time of forced swim in mice, and shows a very good anti-depression effect. Comparison tests show that the compoundpreparation provided by the invention is obviously superior to a single probiotic component or a mineral component and the medicinal and edible component thereof. All the components supplement each other and have a synergistic effect, and the treatment effect is achieved at multiple target points. The compound preparation is safe, effective and free of toxic and side effects.

The invention provides a traditional Chinese medicine preparation for resisting depression and stress mental handicap, which is a medicament prepared from traditional Chinese medicines in the following weight proportion: 9 to 15 portions of Pinellia tuberifera preparata, 9 to 15 portions of rhizoma arisaematis preparata, 9 to 15 portions of dried orange peel, 9 to 30 portions of tuckahoe, 6 to 9 portions of radix bupleuri, 9 to 18 portions of white peony root, 3 to 6 portions of rhizoma coptidis, 9 to 15 portions of angelica, 9 to 15 portions of rhizoma atractylodis macrocephalae, 15 to 30 portions of dragon bone, and 6 to 9 portions of honey-fried licorice root. The invention is to provide the traditional Chinese medicine preparation which comprises active ingredients such as Pinellia tuberifera and rhizoma arisaematis and resists depression and stress metal handicap by applying a phlegm-dissolving depression-relieving method as a core rule to resist depression and stress mental handicap based on TCM phlegm syndrome theory; an animal experiment shows that the preparation can shorten the still time of forced swimming of a mouse and has anti-depression effect, and the anti-depression effect is more apparent than fluoxetine; and through the clinical observation, the medicament can eliminate depression state, apparently improve sleeping quality, and relieve anxiety and tension moods. The invention also provides various oral formulations of the medicament and a preparation method.

The invention provides a special clinical nutrition composition for constipation. The composition comprises the following components in parts by weight: 5-10 parts of fat, 20-35 parts of carbohydrate,45-55 parts of dietary fiber, 0.005-0.02 part of fat soluble vitamin, 0.008-0.2 part of water soluble vitamin, 2-6 parts of dietary essence, 0.1-8 parts of components of homology of medicine and food, 0.1-2 parts of natural phytochemical and 1-7 parts of new resource food. The invention further provides a preparation method of the clinical nutrition composition. The special clinical nutrition composition for constipation can relieve non-physiological changes due to neuroendocrine imbalance, gastrointestinal motility insufficiency, mental stimulation and intestinal morphology, provide clinicalnutrition support and nutrition assistance for constipation patients, and can help the constipation patients to improve body function disorder due to nutrition deficiency.

The invention relates to a new composition of salvia miltiorrhiza and a derivative, a preparation method and application thereof, belonging to the technical field of medicine, wherein the three compositions are salvia miltiorrhiza new lactone A, salvia miltiorrhiza new lactone B and salvia miltiorrhiza new lactone C and derivative thereof and effective parts, which have a (1) chemical structure general formula. The invention also relates to application of a new skeleton composition and a derivative and an effective part thereof on preparing medicine, in particular to the application of same on preparing spiritual class medicine and anticancer class medicine, wherein R1 is selected from hydrogen, alkyl, undersaturated alkyl, hydroxide radical, alkoxyl, carboxyl, esterifiable carboxyl, balmy substituent, halogen, and the like, R2, R3 and R4 are selected from hydrogen, alkyl, undersaturated alkyl, balmy substituent, low grade sugar indican, polysaccharide indican, metallic ions and organic acid ester group, and the R2, the R3 and the R4 can be same and also can be different.

The invention belongs to the technical field of medicine and relates to a pharmaceutical composition with an anti-depression effect. The pharmaceutical composition is prepared from, by weight, 5-100 parts of morinda roots, 5-100 parts of fructus gardenia, 5-100 parts of poria cocos and 1-50 parts of fermented soybeans. The pharmaceutical composition is a refined formula determined with the theory of traditional Chinese medicine as the basis and the modern pharmacological study result as indexes, and can remarkably relieve somatic symptoms such as vigor deficiency, sleep disorder and anorexia of patients while treating mental symptoms such as the amorphous type, hebetude, retardation of thinking and bulesis reduction of depression patients.

The invention discloses a pharmaceutical composition of chlorambucil and medical application of the pharmaceutical composition to anti-depression. The pharmaceutical composition of chlorambucil contains chlorambucil and a natural product compound (I) which is separated out of dry tuberous roots of radix pseudostellariae and is novel in structure, and the chlorambucil and the natural product have a certain anti-depression effect when acting separately; the anti-depression effect is further improved when the chlorambucil and the natural product jointly act, and the pharmaceutical composition can be developed into anti-depression medicine. Compared with the prior art, the pharmaceutical composition of chlorambucil and the medical application of the pharmaceutical composition to anti-depression have outstanding substantive features and remarkable progresses.

The invention discloses a hederagenin amide derivative which is N-(3-dimethylaminopropyl)-hederagenin-17-formamide (HGA). According to the hederagenin amide derivative, 3-dimethylamino propylamine is introduced at the 28th position of the hederagenin, the hederagenin and a drone form a hydrogen bond due to the existence of amino, so that the biological activity of the hederagenin is improved, and an anti-depression effect of the hederagenin is better, and furthermore, a lot of experiments prove that the N-(3-dimethylaminopropyl)-hederagenin-17-formamide also has a good effect in neuroprotection and anti-tumor. The hederagenin amide derivative shows that neuroplasticity and depression are closely related, and a BDNF (brain derived neurotrophic factor) has a certain relationship with depression and is beneficial for the nerve plasticity to recover. The invention also discloses a mechanism studying an HGA neuroprotective effect from the point of view of BDNF and neuroplasticity.

The invention discloses an application of trifolirhizin to preparation of medicines for preventing or treating depression. The trifolirhizin is a flavonoid compound extracted from sophora alopecuroides, is safe and non-toxic in sources, has the effect of resisting depression, can be used for preparing antidepressant medicines, does not produce side effects and is safe and efficient. Besides, the invention also provides an antidepressant medicine. The antidepressant medicine comprises the trifolirhizin and a carrier acceptable for medicines.